Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Rating of “Moderate Buy” by Brokerages

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a consensus recommendation of “Moderate Buy” by the five analysts that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $12.20.

A number of research firms have weighed in on INO. Royal Bank of Canada cut their target price on shares of Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a research report on Wednesday, March 19th. JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. HC Wainwright reaffirmed a “neutral” rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a research report on Wednesday, March 19th. Finally, StockNews.com raised Inovio Pharmaceuticals to a “sell” rating in a research report on Friday, March 21st.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ INO opened at $1.50 on Wednesday. The business’s 50-day simple moving average is $2.00 and its 200-day simple moving average is $3.43. Inovio Pharmaceuticals has a 52 week low of $1.50 and a 52 week high of $13.44. The firm has a market cap of $55.00 million, a price-to-earnings ratio of -0.38 and a beta of 0.92.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.18. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.03 million. As a group, equities research analysts forecast that Inovio Pharmaceuticals will post -4.23 earnings per share for the current year.

Institutional Trading of Inovio Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of INO. Alpine Global Management LLC bought a new stake in Inovio Pharmaceuticals in the 4th quarter valued at $31,000. Stonepine Capital Management LLC acquired a new position in Inovio Pharmaceuticals in the fourth quarter worth about $1,922,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Inovio Pharmaceuticals during the fourth quarter worth about $412,000. Graham Capital Management L.P. acquired a new stake in Inovio Pharmaceuticals during the fourth quarter valued at approximately $114,000. Finally, Deutsche Bank AG grew its stake in shares of Inovio Pharmaceuticals by 524.6% in the 4th quarter. Deutsche Bank AG now owns 89,864 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 75,477 shares during the period. 26.79% of the stock is currently owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.